

# Lumito announces timetable for reverse share split and recalculated terms for outstanding warrants of series T07

**Extraordinary general meeting in Lumito AB (publ) ("Lumito" or the "Company") resolved on 20 January 2026 to carry out a reverse share split. Below, the Company announces the timetable for the reverse share split and the recalculated terms for warrants of series T07.**

## Reverse share split

At the extraordinary general meeting in Lumito AB (publ) on 20 January 2026, a resolution was passed on a reverse share split at a ratio of 1:500, whereby 500 existing shares shall be consolidated into one (1) new share. The extraordinary general meeting authorised the board of directors to set the record date for the reverse share split. Based on this authorisation, the Company's board of directors has decided on 9 February 2026 as the record date for the reverse share split.

Timetable for the reverse share split:

5 February 2026	Last day of trading in Lumito shares before the reverse share split.
6 February 2026	First day of trading in Lumito's shares after the reverse share split. From this date, the share price will reflect the effect of the reverse share split.
9 February 2026	Record date for the reverse share split.

Shareholders do not need to take any action to participate in the reverse share split. As a result of the reverse share split, Lumito's share will change its ISIN code. From 6 February 2026, the share will have the new ISIN code SE0027620956.

Shareholders who, on the record date, do not hold a number of shares that is evenly divisible by 500 will receive, free of charge, as many shares (1–499) as necessary to ensure that the shareholder's holding, after the addition of the shares provided, is evenly divisible by 500 (rounded up). Such adjustment shares will be provided by Euroclear Sweden AB, without any further action being required by the shareholders.

In order to minimise dilution for existing owners, members of the board of directors and certain members of management have undertaken to contribute approximately 4,000,000 adjustment shares from their own shareholdings, without remuneration or compensation of any kind.

After the reverse share split, the number of shares in the Company will amount to 3,440,897. The Company will now also initiate the reduction of the share capital as decided by the general meeting on 20 January 2026. The reduction is expected to be registered with the Swedish Companies Registration Office in approximately two to three months. The new quota value after the reverse share split and reduction will be SEK 3.50 per share.

## Recalculation of terms for T07

Due to the reverse share split and reduction of share capital, the terms for the warrant of series T07 have also been recalculated. The recalculated terms for the warrants are set out below.

- Each warrant of series T07 entitles the holder to subscribe for 0.002 shares in the Company, i.e. 500 warrants of series T07 entitle the holder to subscribe for one (1) new share in the Company.
- The subscription price for subscribing for shares based on warrants of series T07 amounts to seventy (70) per cent of the volume-weighted average price of the Company's share during the period from 7 May 2026 to 21 May 2026, but no less than the share's quotient value of SEK 3.50 per share (after the reduction of the share capital has been registered with the Swedish Companies Registration Office) and no more than SEK 15.50.

The warrants of series T07 may be used to subscribe for new shares in the Company during the period from 25 May 2026 to 5 June 2026. Warrants of series T07 are traded on NGM Nordic SME until 2 June 2026.

## For further information, please contact:

---

Sanna Wallenborg, CEO Lumito  
E-mail: [sw@lumito.se](mailto:sw@lumito.se)  
Ph: +4670-870 01 68

## About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. [www.lumito.se/en/](http://www.lumito.se/en/)

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

## Attachments

[Lumito announces timetable for reverse share split and recalculated terms for outstanding warrants of series T07](#)